N/A N=6 Guide To Goals: A Novel Care Coordination Tool for Children With Type Two Diabetes (T2D)
Type2 Diabetes Mellitus
Primary: Participant Task Completion Rate for Usability Testing Session — 1; 1; 0; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure
Mild Hypertension
Primary: Percent Change From Baseline in Plasma Angiotensinogen (AGT) at Day 43 (Week 7) Compared to Placebo — 12.6; -54.2 percent change — p=<0.001
N/A N=91 QBSAfe: A Novel Approach to Diabetes Management Focused on Quality of Life, Burden of Treatment, Social Integration and Avoidance of Future Events
Diabetes · Diabetes Mellitus
Primary: Acceptability - Patients — 16; 21; 12; 6 Participants
N/A N=101 Choline Nutritional Status: Development of a Biomarker Panel
Healthy
Primary: Ratio of Liver Choline Pool Size by Isotope Dilution — 0.02357; 0.02403; 0.02184; 0.00023 isotopic enrichment ratio — p=0.0247
N/A N=141 Renal Osteodystrophy: An Individual Management Approach
Kidney Failure, Chronic
Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443
Phase 3 N=297 Autologous Muscle Derived Cells for Female Urinary Sphincter Repair
Stress Urinary Incontinence
Primary: Participants With ≥ 50% Reduction in Stress Incontinence Episode Frequency From Baseline to 12 Months Post-treatment; as Assessed by 3 Day Diary — 103; 52 Participants
N/A N=39 Increasing Physical Activity in Older Adults With Osteoarthritis Pain: Examining a Brief Behavioral Intervention
Osteoarthritis, Knee · Osteoarthritis, Hip
Primary: Number of Participants Enrolled in the Study — 19; 20 Participants
Phase 3 N=333 A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
Respiratory Tract Diseases · Abnormal Mucus Secretions
Primary: Change From Baseline to Day 7 of Mean Sputum Viscosity Score of NAC and Placebo — -1.2; -1.0 Score — p=<0.001
N/A N=10 A Cluster-randomized Controlled Knowledge Translation Feasibility Study in Alberta Community Pharmacies
Chronic Diseases
Primary: Change in Service Counts From Baseline to End of Intervention Period — 172; 284; 121; 166 Billable pharmacy services
N/A N=80 Improving Metabolic Health in Patients With Diastolic Dysfunction
Obesity · Heart Failure, Diastolic · Metabolic Syndrome
Primary: Change From Baseline at 1 Year in Myocardial Lipid Content — -0.16; -0.18; -0.53; -0.19 %fat/water
Phase 3 N=30 Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks
Fabry Disease
Primary: Number of Participants With Treatment-related Adverse Events (TEAE) as Assessed by CTCAE v4.03 — 27; 26; 2; 2 participants
Phase 2 N=1,541 A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2
Coronavirus Disease
Primary: Cohort 1: Percentage of Participants With Serological Response Against SARS-CoV-2 Original Strain 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary…
N/A N=359 Assessing the Effect of a Blood-based Colorectal Cancer Screening Test on Screening Adherence and Colonoscopy Completion
Colorectal Cancer
Primary: Percentage of Participants Who Undergo Screening Within 6 Months of Outreach — 17; 31 Participants
Phase 4 N=40 Efficacy Of Quadratus Lumborum II Block For Laparoscopic Sleeve Gastrectomy
Morbid Obesity · High BMI
Primary: The Amount of Opioid Consumption During and After Procedure — 26.3; 27.1; 5.49; 5.52 mg IV morphine equivalents
Phase 3 N=102 Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants